酮体3-羟基丁酸对慢性心力衰竭患者的心血管效应
该研究在射血分数降低的心衰(HFrEF)患者中,通过交叉设计输注3-羟基丁酸(3-OHB)或安慰剂,发现3-OHB升高循环水平并增加心输出量、每搏量和心率,且呈剂量依赖关系;3-OHB增加心肌氧耗但不影响心肌外部能量效率,HFrEF患者与年龄匹配志愿者的反应无差异。
要点
- 3-OHB输注使HFrEF患者心输出量增加2.0±0.2 L/min,每搏量增加20±2 mL,心率增加7±2 bpm。
- 血浆3-OHB达0.7 mM时心输出量已显著增加0.3 L/min,呈剂量依赖关系。
- 3-OHB增加心肌氧耗但不改变心肌外部能量效率,HFrEF与志愿者反应相似。
核心结论
- 3-OHB对HFrEF患者具有有益的血流动力学效应,且不损害心肌外部能量效率。
- 该效应在生理循环浓度范围内即可检测到,HFrEF患者与年龄匹配志愿者反应无差异。
- 3-OHB可能成为HFrEF患者的一种新型治疗原则。
研究设计与样本
- 研究1:16例慢性HFrEF患者(左室射血分数37±3%)随机交叉接受3小时3-OHB或安慰剂输注,采用Swan-Ganz导管和超声心动图监测。
- 研究2:8例HFrEF患者接受递增速率3-OHB输注的剂量反应研究。
- 研究3至4:10例HFrEF患者和10例年龄匹配志愿者随机交叉接受3小时3-OHB或安慰剂输注,用11C-乙酸盐正电子发射断层扫描评估心肌外部能量效率和心肌氧耗。
主要发现
- 3-OHB输注使血浆3-OHB从0.4±0.3升至3.3±0.4 mM(P<0.001)。
- 心输出量增加2.0±0.2 L/min(P<0.001),因每搏量增加20±2 mL(P<0.001)和心率增加7±2 bpm(P<0.001)。
- 左室射血分数数值上增加8±1%(P<0.001)。
- 血浆3-OHB达0.7 mM时心输出量已显著增加0.3 L/min(P<0.001),呈剂量反应关系。
- 3-OHB增加心肌氧耗但不改变心肌外部能量效率;HFrEF患者与年龄匹配志愿者的心肌外部能量效率和心输出量反应无差异。
临床怎么用
- 3-OHB输注可改善HFrEF患者血流动力学,且不损害心肌能量效率,支持其作为潜在治疗原则。
- 效应在生理浓度范围(低至0.7 mM)即可出现,提示可通过调节循环酮体水平探索治疗。
- HFrEF患者与年龄匹配志愿者的血流动力学和能量效率反应相似,支持进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial utilization of 3-hydroxybutyrate (3-OHB) is increased in patients with heart failure and reduced ejection fraction (HFrEF). However, the cardiovascular effects of increased circulating plasma-3-OHB levels in these patients are unknown. Consequently, the authors' aim was to modulate circulating 3-OHB levels in HFrEF patients and evaluate: (1) changes in cardiac output (CO); (2) a potential dose-response relationship between 3-OHB levels and CO; (3) the impact on myocardial external energy efficiency (MEE) and oxygen consumption (MVO2); and (4) whether the cardiovascular response differed between HFrEF patients and age-matched volunteers. METHODS: Study 1: 16 chronic HFrEF patients (left ventricular ejection fraction: 37±3%) were randomized in a crossover design to 3-hour of 3-OHB or placebo infusion. Patients were monitored invasively with a Swan-Ganz catheter and with echocardiography. Study 2: In a dose-response study, 8 HFrEF patients were examined at increasing 3-OHB infusion rates. Study 3 to 4: 10 HFrEF patients and 10 age-matched volunteers were randomized in a crossover design to 3-hour 3-OHB or placebo infusion. MEE and MVO2 were evaluated using 11C-acetate positron emission tomography. RESULTS: 3-OHB infusion increased circulating levels of plasma 3-OHB from 0.4±0.3 to 3.3±0.4 mM ( P<0.001). CO rose by 2.0±0.2 L/min ( P<0.001) because of an increase in stroke volume of 20±2 mL ( P<0.001) and heart rate of 7±2 beats per minute (bpm) ( P<0.001). Left ventricular ejection fraction increased 8±1% ( P<0.001) numerically. There was a dose-response relationship with a significant CO increase of 0.3 L/min already at plasma-3-OHB levels of 0.7 mM ( P<0.001). 3-OHB increased MVO2 without altering MEE. The response to 3-OHB infusion in terms of MEE and CO did not differ between HFrEF patents and age-matched volunteers. CONCLUSIONS: 3-OHB has beneficial hemodynamic effects in HFrEF patients without impairing MEE. These beneficial effects are detectable in the physiological concentration range of circulating 3-OHB levels. The hemodynamic effects of 3-OHB were observed in both HFrEF patients and age-matched volunteers. 3-OHB may potentially constitute a novel treatment principle in HFrEF patients.
引用
- Nielsen R, Møller N, Gormsen LC, et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019. PMID: 30884964. doi:10.1161/CIRCULATIONAHA.118.036459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。